Injectable PrEP formulations are a promising intervention for increasing PrEP effectiveness and reducing disparities in HIV transmission, particularly among communities of color, youth, cis-women, transgender and gender diverse communities. In this webinar, Dr. Al Liu provided updates on the latest clinical data for lenacapavir injectable PrEP medication, and along with Whitman-Walker Health colleagues, discussed overcoming barriers to implementation for clinicians, health departments and CBOs.
About the speaker:
Dr. Albert Liu, MD, MPH is the Clinical Research Director of Bridge HIV within the San Francisco Department of Public Health and a Clinical Professor of Medicine at University of California, San Franciso. As a leader in HIV prevention research, he conducts clinical trials of novel PrEP agents and evaluates implementation strategies to support the equitable scale-up of PrEP in real-world settings. He also serves as co-chair of the PrEP Committee of the San Francisco Getting to Zero Consortiums and is an attending physician at San Francisco General Hospital.
